ArticleHepatology (Baltimore, Md.)2022
Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC.
Article in Hepatology (Baltimore, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06231160 (Clinical Comparative Study of Systematic Therapy Combined With Microwave Ablation and Systematic Therapy for Pancreatic Cancer), which is not on this map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Comparative Study of Systematic Therapy Combined With Microwave Ablation and Systematic Therapy for Pancreatic Cancer
Who cites it
61 citing papers in PubMed, 126 citations in OpenAlex.
- Ultrasound-guided percutaneous microwave ablation of splenic solid lesions: experience in a rare cohort.Abdominal radiology (New York) · 2026Article
- TRMT6-Mediated mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- A bibliometric analysis of research trends and hotspots on recurrence after thermal ablation for hepatocellular carcinoma 2005-2025.Discover oncology · 2026Article
- Sustained virological response improved survival outcomes after curative resection in patients with hepatitis C virus-related hepatocellular carcinoma in the era of direct‑acting antiviral therapy.Updates in surgery · 2026Article
- Microwave Ablation with or without TACE for Unresectable Large Hepatocellular Carcinoma: Impact of Tumor Burden Score on Efficacy.Journal of gastrointestinal cancer · 2026Article
- Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The local efficacy and influencing factors of ultrasound-guided percutaneous radiofrequency ablation in sub-cardiac hepatic tumor: A 7-year experience at a single center.Abdominal radiology (New York) · 2026Article
- Nanozyme for precision treatment of hepatocellular carcinoma.Materials today. Bio · 2026Review
- Identifying the Optimal Treatment for Patients with Hepatocellular Carcinoma and Clinically Significant Portal Hypertension: A Multicenter Propensity Score-Weighted Analysis.Annals of surgical oncology · 2026Article
- Spatial multiomics reveals irreversible electroporation-induced immuno-metabolic characteristics of the inflammatory margin in liver cancer.Communications biology · 2026Article
- Clinical efficacy of MWA via the caudal‒cranial direction puncture pathway for small hepatocellular carcinoma at the hepatic dome: 3 years of follow-up.BMC surgery · 2026Article
- Trans-Arterial Chemoembolization Combined with Microwave Ablation versus Microwave Ablation Alone for 3-5 cm Hepatocellular Carcinoma: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
- Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication.Cardiovascular and interventional radiology · 2026Article
- Prediction of Tumor Progression After Microwave Ablation of Hepatocellular Carcinoma by Contrast-Enhanced Ultrasound Combined with Immunohistochemical Markers.Journal of hepatocellular carcinoma · 2026Article
- Risk Model for Predicting Aggressive Recurrence of Hepatocellular Carcinoma after Microwave Ablation Using MRI and Clinical Parameters.Radiology. Imaging cancer · 2026Article
- Development and Validation of a LASSO-RF-Cox-Derived Nomogram Incorporating Inflammatory Markers to Predict Long-Term Survival in Early-Stage Hepatocellular Carcinoma After Microwave Ablation.Journal of hepatocellular carcinoma · 2026Article
- Downstaging therapy of intermediate-stage hepatocellular carcinoma: microwave ablation vs. surgical resection.Frontiers in oncology · 2026Article
- Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma: A retrospective study.World journal of gastroenterology · 2025Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
37 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe study objective was to compare the effectiveness of microwave ablation (MWA) and laparoscopic liver resection (LLR) on solitary 3-5-cm HCC over time. APPROACH AND
resultsFrom 2008 to 2019, 1289 patients from 12 hospitals were enrolled in this retrospective study. Diagnosis of all lesions were based on histopathology. Propensity score matching was used to balance all baseline variables between the two groups in 2008-2019 (n = 335 in each group) and 2014-2019 (n = 257 in each group) cohorts, respectively. For cohort 2008-2019, during a median follow-up of 35.8 months, there were no differences in overall survival (OS) between MWA and LLR (HR: 0.88, 95% CI 0.65-1.19, p = 0.420), and MWA was inferior to LLR regarding disease-free survival (DFS) (HR 1.36, 95% CI 1.05-1.75, p = 0.017). For cohort 2014-2019, there was comparable OS (HR 0.85, 95% CI 0.56-1.30, p = 0.460) and approached statistical significance for DFS (HR 1.33, 95% CI 0.98-1.82, p = 0.071) between MWA and LLR. Subgroup analyses showed comparable OS in 3.1-4.0-cm HCCs (HR 0.88, 95% CI 0.53-1.47, p = 0.630) and 4.1-5.0-cm HCCs (HR 0.77, 95% CI 0.37-1.60, p = 0.483) between two modalities. For both cohorts, MWA shared comparable major complications (both p > 0.05), shorter hospitalization, and lower cost to LLR (all p < 0.001).
conclusionsMWA might be a first-line alternative to LLR for solitary 3-5-cm HCC in selected patients with technical advances, especially for patients unsuitable for LLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.